Antipsychotic Agent
Odds for injurious fall heightened with fall-risk increasing drug prescription in COPD
The adjusted likelihood for an injurious fall in adults with COPD was elevated with a fall-risk increasing drug prescription, according to results published in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation.
New agent may help halt weight gain caused by antipsychotic drug
SAN ANTONIO —An intestinal microsomal triglyceride transfer protein inhibitor reduced postprandial triglycerides and halted weight gain in patients treated with the antipsychotic olanzapine, according to results of a pilot study.
The inside story of Cobenfy
Obscured by the celebratory congratulations and profuse praise of the scientific advance marked by the FDA’s approval of KarXT, now branded Cobenfy, is the revealing and instructive story of how this novel therapeutic agent came to fruition.
FDA approves first new class of schizophrenia treatment in more than 30 years
The FDA has approved Cobenfy, formerly known as KarXT, a muscarinic acetylcholine receptor agonist for the treatment of schizophrenia in adults.
Safety of TV-46000, long-acting injection for schizophrenia, consistent in phase 3 study
Among patients with schizophrenia, TV-46000 had a favorable safety profile that was consistent with other formulations of risperidone and previous studies of TV-46000, according to a study published in CNS Drugs.
Bristol Myers acquires Karuna, including novel muscarinic neuropsychiatric drug
Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.
Two antipsychotic drugs prolong QTc interval, may cause arrhythmias, sudden cardiac death
The antipsychotic drugs quetiapine and haloperidol were associated with severe QT prolongation, ventricular arrhythmias and sudden cardiac death, researchers reported in HeartRhythm.
Targeting Novel Pathways to Address Unmet Needs in Schizophrenia Treatment
This activity is supported by an educational grant from Karuna Therapeutics.
Karuna Therapeutics submits new drug application to FDA for schizophrenia treatment
Karuna Therapeutics Inc. has submitted a new drug application to the FDA for KarXT, its investigational muscarinic antipsychotic for the treatment of schizophrenia.
Antipsychotic use in children plummets from 2008 to 2016
The prevalence of antipsychotic use in children under Medicaid substantially declined from 2008 to 2016, according to a study published in Health Affairs.